NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells

Area of Science:

• Molecular Biology
• Cancer Research
• Genetics

Background:

• Drug resistance is a primary cause of cancer therapy failure.
• Cancer cells develop multiple resistance mechanisms during tumor progression.
• Nuclear factor-kappa B (NF-kappaB) is implicated in apoptosis inhibition and drug resistance.

Purpose of the Study:

• To investigate the role of NF-kappaB in regulating mdr1 gene expression and drug resistance in colon cancer cells.
• To determine if NF-kappaB inhibition affects daunomycin sensitivity and uptake in HCT15 cells.

Main Methods:

• Utilized HCT15 colon cancer cells.
• Inhibited NF-kappaB using a plasmid encoding a mutated IkappaB-alpha inhibitor.
• Assessed daunomycin-induced apoptosis and cellular uptake.
• Measured mdr1 mRNA and P-glycoprotein expression levels.
• Identified and validated NF-kappaB binding sites in the mdr1 gene promoter and intron.
• Employed a luciferase reporter assay to assess NF-kappaB transactivation of the mdr1 promoter.

Main Results:

• Inhibition of NF-kappaB or P-glycoprotein increased apoptotic cell death in response to daunomycin.
• NF-kappaB inhibition enhanced daunomycin cellular uptake.
• NF-kappaB inhibition led to reduced mdr1 mRNA and P-glycoprotein expression.
• A functional NF-kappaB binding site was identified in the first intron of the human mdr1 gene.
• NF-kappaB was shown to transactivate the mdr1 promoter.

Conclusions:

• NF-kappaB plays a significant role in regulating mdr1 gene expression in cancer cells.
• NF-kappaB contributes to drug resistance by modulating mdr1 expression.
• Targeting NF-kappaB may represent a viable strategy to overcome drug resistance in cancer therapy.